EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Abietic acid targets RAN to restrict coxsackievirus B3 infection

Junbo Huang, Qing Song, Yanjun Di, Zhiyun Cheng, Zhaocheng Yang, Xibo Lin, Kaiyuan Hunag, Haoyi Zhan, Lijuan Xie, Jieqing Liu, Lei Tong

Frontiers in Microbiology · 16.06.2026 · 17

DOI: 10.3389/fmicb.2026.1874898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 16.06.2026. Verfasst von Junbo Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Huaqiao University, Quanzhou, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coxsackievirus B3 (CVB3) represents a major etiological factor of viral myocarditis (VMC). It frequently results in the damage of the heart and even heart failure, but there are few effective treatment measures that can be used clinically. In this paper, we show that abietic acid (AA), a tricyclic diterpenoid compound, has strong anti-CVB3 activity both in vitro and in vivo . AA was found to inhibit CVB3 replication with 50% effective concentration (EC50) of 12.16 μM and high selectivity index (SI = 26.90) and 50 percent cytotoxic concentration (CC50) of 327.14 μM in HeLa cells, suggesting good biosafety. Mechanistically, RAN (Ras-related nuclear protein) a central mediator of nucleocytoplasmic transport was determined to be an essential host dependency factor in CVB3 replication. The AA therapy led to a significant decrease in RAN expression, thus recovering nuclear translocation of phosphorylated STAT1/2 (p-STAT1/2) compromised by CVB3 infection, which subsequently boosts the response of interferon-stimulated genes (ISGs) downstream. AA treatment in a CVB3-induced model of murine myocarditis showed a significant increase in survival rates, lower viral loads and inflammatory cytokines in cardiac tissues, and lessened myocardial injury. Collectively, these results identify RAN as a novel antiviral target, and show that AA inhibits CVB3 infection via the RAN-p-STAT1/2 axis, supporting its potential as a promising therapeutic agent for CVB3-associated diseases.

Schlagwörter

Stichwörter der Autor:innen

Ras-related nuclear proteinabietic acidantiviralcoxsackievirus B3phosphorylated STAT1/2

Autor:innen und Institutionen

  • School of Medicine, Huaqiao University, Quanzhou, China.

Zitieren

APA

Huang, J., Song, Q., Di, Y., Cheng, Z., Yang, Z., Lin, X., Hunag, K., Zhan, H., Xie, L., Liu, J., & Tong, L. (2026). Abietic acid targets RAN to restrict coxsackievirus B3 infection. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1874898

Vancouver

Huang J, Song Q, Di Y, Cheng Z, Yang Z, Lin X, et al. Abietic acid targets RAN to restrict coxsackievirus B3 infection. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1874898

BibTeX
@article{Huang2026,
  author = {Huang, Junbo and Song, Qing and Di, Yanjun and Cheng, Zhiyun and Yang, Zhaocheng and Lin, Xibo and Hunag, Kaiyuan and Zhan, Haoyi and Xie, Lijuan and Liu, Jieqing and Tong, Lei},
  title = {Abietic acid targets RAN to restrict coxsackievirus B3 infection},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.1874898}
}
Kostenlos starten →